Drugs that contain Eluxadoline
1. Viberzi patents expiration
VIBERZI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8609709 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US7786158 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US10213415 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US9115091 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
| US8691860 | ABBVIE | Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
| US7741356 | ABBVIE | Compounds as opioid receptor modulators |
May, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9205076 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US9700542 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US8772325 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US8344011 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(10 months from now) | |
| US9364489 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
| US9789125 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(4 years from now) | |
| US11007179 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11229627 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11090291 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11311516 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US9675587 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11160792 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US10188632 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| US11484527 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2020 |
NCE-1 date: 28 May, 2019
Market Authorisation Date: 27 May, 2015
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Reduction of the frequency of abdominal pain and diarrhea, in an inflammatory bowel disease with diarrhea (ibs-...
Dosage: TABLET;ORAL
How can I launch a generic of VIBERZI before it's drug patent expiration?
More Information on Dosage
VIBERZI family patents
